Charles Duncan

Jason Gerberry

Asim Rana

Benjamin Paluch

Felix Ampomah

Joel Beatty

Joon Lee

Samantha Semenkow

Jennifer Kim

Joseph Catanzaro

Leland Gershell

Pavan Patel

Rohan Mathur

Sudan Loganathan

- **Catalyst Pharmaceuticals** and its licensor **SERB S.A.** have reached a **settlement agreement** with **Lupin Ltd** and **Lupin Pharmaceuticals, Inc.**, resolving patent litigation concerning Lupin's generic version of **FIRDAPSE®** (amifampridine) 10 mg tablets.  **[1369568_56ac8ad90020434090274adc62a19e30_0]** 
- Pursuant to the agreement, **Lupin** will not market its generic **FIRDAPSE** in the United States any earlier than **February 25, 2035**, unless certain limited circumstances occur.  **[1369568_56ac8ad90020434090274adc62a19e30_0]** 
- This settlement terminates all ongoing patent litigation between Catalyst/SERB and Lupin regarding FIRDAPSE patents, though patent litigation against **Hetero** remains ongoing.  **[1369568_56ac8ad90020434090274adc62a19e30_0]**

Catalyst Pharmaceuticals Settles FIRDAPSE Patent Litigation with Lupin

CATALYST PHARMACEUTICALS (CPRX)